Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
| ▸ | GPR183 | P32249 | 1/20 | 0.55 |
| ▸ | GHSR | Q92847 | 2/20 | 0.52 |
| ▸ | FASN | P49327 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 1/20 | 0.51 |
| ▸ | NUDT15 | Q9NV35 | 1/20 | 0.49 |
| ▸ | OXTR | P30559 | 1/20 | 0.48 |
| ▸ | CCR3 | P51677 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386763 | 0.89 | MAPK14 (0.62) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL30066210 | 0.89 | MAPK14 (0.62) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL30226931 | 0.85 | MAPK14 (0.64) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL22216445 | 0.85 | MAPK14 (0.64) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL30329646 | 0.85 | MAPK14 (0.64) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL8534513 | 0.85 | MAPK14 (0.64) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL29944365 | 0.84 | MAPK14 (0.63) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL2214616 | 0.84 | MAPK14 (0.63) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL3457123 | 0.84 | MAPK14 (0.63) | MAPK14GPR183GHSRFASNDRD2 | |
| SCHEMBL3039407 | 0.82 | MAPK14 (0.64) | MAPK14GPR183GHSRFASNDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034121-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2025-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034121-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | GPR183, GPR180, GPR65 | MAPK14 2778/4885GPR183 1/4885GHSR 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.